Transition Therapeutics Inc (TTHI)
Transition Therapeutics is a biopharmaceutical company based in Canada. Co. is engaged in developing therapeutics for central nervous system (CNS) and metabolic disease indications. Co.'s technologies are focused on the treatment of Alzhemier's disease and diabetes. Co.'s products include ELND005 (AZD-103) for the treatment of Alzheimer's disease; TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, Alzheimer's disease, traumatic brain injury, intracerebral haemorrhage, and others; and TT401/402 for the treatment of diabetes.
|
March 29, 2024 10:52 AM Eastern
|